Leonard Braden Michael's Form 4 filing
Adverum Biotechnologies, Inc. (ADVM) · filed Apr 24, 2025
- Accession no.
- 0001373604-25-000065
- Filed
- Apr 24, 2025
- Trade date
- Apr 22-23, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $1.05M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leonard Braden MichaelCIK 0001373603 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 22, 2025 | Common Stock | PPurchaseAcquired | +300,000 | $3.00 | +$900,000 | 3,057,526 | Indirect | |
| Apr 23, 2025 | Common Stock | PPurchaseAcquired | +50,000 | $2.98F2 | +$149,000 | 191,800 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents shares purchased in multiple transactions resulting in a weighted average purchase price of $2.979 per share. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares bought at each separate price within the range.
Referenced by the price of 1 transaction in Table I.